Andrea Rocca

Summary

Publications

  1. doi request reprint Benefit from anthracyclines in relation to biological profiles in early breast cancer
    Andrea Rocca
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Via Maroncelli 40, 47014, Meldola FC, Italy
    Breast Cancer Res Treat 144:307-18. 2014
  2. doi request reprint Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer
    Andrea Rocca
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Department of Medical Oncology, Meldola, Italy 39 0543 739100 39 0543 739151
    Expert Opin Pharmacother 15:407-20. 2014
  3. doi request reprint A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer
    Andrea Rocca
    Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, via P Maroncelli 40, 47014 Meldola, FC, Italy
    Cancer Chemother Pharmacol 65:871-6. 2010
  4. pmc A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
    A Rocca
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy
    Br J Cancer 100:28-36. 2009
  5. ncbi request reprint Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy
    Cancer Chemother Pharmacol 62:667-72. 2008
  6. ncbi request reprint Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer
    Andrea Rocca
    Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Anticancer Res 29:5111-9. 2009
  7. pmc Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BMC Cancer 6:225. 2006
  8. ncbi request reprint A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
    Andrea Rocca
    Unit of Research in Medical Senology, Department of Medicine, Division of Pathology, University of Milan School of Medicine, Italy
    Anticancer Drugs 17:1201-9. 2006
  9. doi request reprint Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
    Rosalba Torrisi
    Research Unit in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 17:654-60. 2008
  10. doi request reprint Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008

Detail Information

Publications23

  1. doi request reprint Benefit from anthracyclines in relation to biological profiles in early breast cancer
    Andrea Rocca
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Via Maroncelli 40, 47014, Meldola FC, Italy
    Breast Cancer Res Treat 144:307-18. 2014
    ..45,95 % CI 0.26-0.78, P = 0.005) and OS (HR 0.30, 95 % CI 0.15-0.63, P = 0.001). Epirubicin-containing regimens seem to be superior to CMF alone in patients with highly proliferating, triple negative or triple unfavorable tumors . ..
  2. doi request reprint Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer
    Andrea Rocca
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Department of Medical Oncology, Meldola, Italy 39 0543 739100 39 0543 739151
    Expert Opin Pharmacother 15:407-20. 2014
    ..Palbociclib (PD 0332991) , a potent and selective inhibitor of CDK4 and CDK6, inhibits proliferation of several Rb-positive cancer cell lines and xenograft models...
  3. doi request reprint A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer
    Andrea Rocca
    Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, via P Maroncelli 40, 47014 Meldola, FC, Italy
    Cancer Chemother Pharmacol 65:871-6. 2010
    ..We conducted a dose-finding study of the combination of liposomal doxorubicin and capecitabine in patients with pretreated metastatic breast cancer...
  4. pmc A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
    A Rocca
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy
    Br J Cancer 100:28-36. 2009
    ....
  5. ncbi request reprint Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy
    Cancer Chemother Pharmacol 62:667-72. 2008
    ..No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors...
  6. ncbi request reprint Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer
    Andrea Rocca
    Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Anticancer Res 29:5111-9. 2009
    ..The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear...
  7. pmc Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BMC Cancer 6:225. 2006
    ..We therefore tested the activity of the combination of Trastuzumab with metronomic, low dose chemotherapy with cyclophosphamide (CTX) and methotrexate (MTX) in metastatic breast cancer (MBC)...
  8. ncbi request reprint A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
    Andrea Rocca
    Unit of Research in Medical Senology, Department of Medicine, Division of Pathology, University of Milan School of Medicine, Italy
    Anticancer Drugs 17:1201-9. 2006
    ..Perioperative chemotherapy failed to show an increase in the pathological complete remission rate. A biological effect on Ki-67 expression was demonstrated...
  9. doi request reprint Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
    Rosalba Torrisi
    Research Unit in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 17:654-60. 2008
    ..Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer...
  10. doi request reprint Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008
    ..Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more active than metronomic therapy alone in preclinical and clinical studies...
  11. ncbi request reprint Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy
    Maria Teresa Sandri
    Unit of Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Cancer 110:509-17. 2007
    ..The aim of the study was to evaluate the prognostic and predictive role of serum HER-2/neu and serum EGFR in breast cancer patients treated with low-dose chemotherapy...
  12. doi request reprint Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer
    Dino Amadori
    Cancer Institute of Romagna I R S T, Meldola, Italy
    Breast Cancer Res Treat 125:775-84. 2011
    ..Further molecular characterization of the tumors might help to identify subgroups achieving higher benefit from either sequence...
  13. ncbi request reprint Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression
    Andrea Rocca
    Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Cancer Chemother Pharmacol 61:965-71. 2008
    ..The aim of the present study was to ascertain the predictive value of p63 immunoreactivity in patients treated preoperatively with regimens including cisplatin and/or anthracyclines...
  14. doi request reprint Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors
    Alberto Farolfi
    Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Via Piero Maroncelli 40, Meldola 47014, Italy
    Heart 99:634-9. 2013
    ..We retrospectively assessed the incidence of TIC and heart failure (HF) to identify possible risk and protective factors...
  15. ncbi request reprint Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer
    Franco Nole
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 6:518-24. 2006
    ....
  16. doi request reprint Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents
    Cristina Noberasco
    Clinical Pharmacology and New Drugs Development Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Oncology 77:358-65. 2009
    ..alpha-Interferon, thalidomide and celecoxib inhibit tumour angiogenesis by differing mechanisms...
  17. ncbi request reprint Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Drugs 17:961-7. 2006
    ..Metronomic chemotherapy can induce prolonged clinical benefit in metastatic breast cancer, supporting its role as an additional therapeutic tool in the treatment of patients with metastatic breast carcinoma...
  18. ncbi request reprint Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:73-80. 2007
    ..Further studies combining chemotherapy and endocrine agents are warranted in patients with hormone receptor-positive tumors...
  19. doi request reprint Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer
    Katia Lorizzo
    Department of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Cancer Chemother Pharmacol 64:301-6. 2009
    ..Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates...
  20. doi request reprint Circulating endothelial cell number and viability are reduced by exposure to high altitude
    Patrizia Mancuso
    Division of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Endothelium 15:53-8. 2008
    ..These data suggest a unique pattern of modulation of surrogate markers of vascular remodeling induced by exposure to hypobaric hypoxia...
  21. pmc Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
    Elisabetta Munzone
    Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res 8:R4. 2006
    ..These sequences of events indicate that a phenotype based on ER expression may not be a permanent feature of breast cancer...
  22. ncbi request reprint Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer
    Chiara Catania
    Division of Medical Oncology, Day Hospital Unit and Unit of Psycho oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 92:265-72. 2005
    ..The questionnaire was shown to be robust, reliable and reproducible instrument in assessing patients' prejudices towards oral anticancer treatments...
  23. doi request reprint Perfusion computed tomography for monitoring induction chemotherapy in patients with squamous cell carcinoma of the upper aerodigestive tract: correlation between changes in tumor perfusion and tumor volume
    Giuseppe Petralia
    Department of Radiology, European Institute of Oncology, Milan, Italy
    J Comput Assist Tomogr 33:552-9. 2009
    ..The aim of this study was to assess the potential of perfusion computed tomography (CTp) for monitoring induction chemotherapy in patients with squamous cell carcinoma (SCCA) of the upper aerodigestive tract...